Acting pharmacologically on different transmitter systems has been suggested to have some advantages in patients with substance abuse and may possibly address a larger spectrum of symptoms. One major drawback of using antidepressants addressing several neurotransmitters is that the relative activities on the different neurotransmitters cannot individually be adjusted. Combining antidepressants targeting different neurotransmitter systems may allow adapting the effect on each neurotransmitter system corresponding to patients' response and tolerance. Three cases of patients presenting a substance use disorder with comorbid major depression episodes are presented, who were treated with a reboxetine/escitalopram combination and who showed a rapid response of their depressive syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pnpbp.2004.10.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: To explore how women who used substances during the perinatal period perceived the care they received from interprofessional perinatal care providers.
Design: Appreciative inquiry.
Setting: Interprofessional perinatal care clinic in a large urban tertiary care hospital in Canada.
Risks associated with opioid prescriptions for headache in the emergency department.
Am J Emerg Med
January 2025
Departments of Emergency Medicine (EM) and Community Health Sciences, University of Calgary, Canada.
Study Hypothesis: Use of opioids for treatment of headache in the emergency department (ED) is associated with an increased 1-year risk of opioid-related adverse events.
Objective: To assess the safety and efficacy of opioid prescribing for ED patients with headache.
Methods: We performed a multicenter observational cohort study using linked administrative data.
Working effectively with individuals with substance use disorders: a qualitative descriptive study.
Br J Nurs
January 2025
Director, Practice Innovation, Standards and Measurement, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Background: Irrespective of where nurses work, they may provide care to individuals with substance use disorders. Unfortunately, some nurses may not understand how to work with these individuals and stigmatisation may occur.
Aim: To explore how to provide effective care for these individuals.
Pharmacist-Directed Transition of Care Services Decrease Readmissions at a Safety-Net Hospital.
Ann Pharmacother
January 2025
Hennepin Healthcare, Minneapolis, MN, USA.
Background: Limited data exist describing the influence of pharmacist-led transition of care (TOC) services in safety-net hospital settings.
Objective: This analysis assessed the impact of pharmacist-led TOC services on hospital readmissions in a high-risk managed Medicaid population impacted by housing instability, substance use disorder (SUD), and mental health issues.
Methods: A retrospective evaluation of patients who received safety-net hospital-based TOC pharmacy services between January 1, 2022, and December 31, 2022, was conducted.
Evaluation of Biologics ACE2/Ang(1-7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies.
Pharmaceutics
December 2024
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
For several decades, protein drugs (biologics) made in cell cultures have been delivered as sterile injections, decreasing their affordability and patient preference. Angiotensin Converting Enzyme 2 (ACE2) gum is the first engineered human blood protein expressed in plant cells approved by the FDA without the need for purification and is a cold-chain and noninvasive drug delivery. This biologic is currently being evaluated in human clinical studies to debulk SARS-CoV-2 in the oral cavity to reduce coronavirus infection/transmission (NCT00543318).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!